[ad_1]
The Institute of Public Health (ISP) ordered the preventive withdrawal of a group of drugs to treat high blood pressure. These are those containing valsartan after detecting an impurity, called N-nitrosodimethylamine or NDMA, that could potentially be carcinogenic.
This active ingredient, manufactured by Zhejing Hiahai Pharmaceutical Co, supplier of various laboratories in the world, is present in other substances such as tobacco smoke, some processed foods and toiletries. Although there is no report that this substance causes cancer in humans, the International Agency for Research on Cancer has clbadified it as "probably carcinogenic to humans" .
the ISP ordered the withdrawal of products containing valsartan from Chinese society. The holders of the sanitary register badigned to this measure are as follows:
- Chemopharma
- Eurofarma Chile
- Galenicum Health Chile SpA
- Chile Laboratory
- Laboratorios Andrómaco
- Laboratorios Lafi Ltda
- Recalcine Laboratories
- Mintlab Co.
- Invested Pharmaceuticals of Chile
What to do if you take any of these medications?
The ISP recommends that patients taking medication with this compound do the following.
- Do not suspend the transaction. It is therefore a precautionary warning, and the sudden suspension of the drug can generate severe seizures.
- Consider that there are several alternatives. For this, consult your specialist or chemist chemist.
- If it is necessary to replace your medications, eliminate the remaining units to prevent their consumption by mistake.
For more details, reviews the document published by the health authority.
[ad_2]
Source link
